The Diabetic Neuropathy by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Diabetic Neuropathy Market:
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
According to The Business Research Company’s Diabetic Neuropathy, The diabetic neuropathy market size has grown strongly in recent years. It will grow from $5.4 billion in 2023 to $5.85 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased awareness and diagnosis, advancements in diabetic care, growing healthcare expenditure, research and development investments, patient education initiatives..
The diabetic neuropathy market size is expected to see strong growth in the next few years. It will grow to $8.42 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in neuroimaging, patient-centric care approaches, expansion of clinical trials, continued rise in diabetes cases, precision medicine approaches, expansion of regenerative medicine, patient advocacy and support programs.. Major trends in the forecast period include collaborative efforts in medical research, digital health solutions, advancements in diagnostic technologies, neuroprotective therapies, personalized treatment strategies, integration of artificial intelligence..
The rising prevalence of diabetes is expected to boost the growth of the diabetic neuropathy market going forward. Diabetes is a persistent disorder where the body struggles to use and store glucose appropriately (a type of sugar). Diabetes occurs when the body either does not create enough insulin (a hormone that aids in blood sugar regulation) or does not use insulin effectively. Diabetic neuropathy is a type of nerve injury that can occur in diabetics with d different forms of nerve damage causing different symptoms. For instance, in August 2022, according to the IDF Diabetes Atlas report published by the International Diabetes Federation, a Belgium-based global diabetes community and an umbrella organization of over 230 national diabetes associations, 6.7 million deaths were attributed to diabetes in the year 2021, which is equivalent to one death every five seconds. There are currently 537 million adults (aged 20–79) living with diabetes, or 1 in 10 people. It is estimated that this number will increase to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic neuropathy market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9057&type=smp
The diabetic neuropathy market covered in this report is segmented –
1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
2) By Drug Class: Analgesics, Anti-Depressants, Anti-consulvants, Other Drug Classes
3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments
4) By Distribution Channel: Online Distribution, Offline Distribution
5) By End-user: Hospitals, Specialty Clinics, Other End-users
Major companies operating in the diabetic neuropathy market are focused on providing innovative solutions to strengthen their position in the market. For instance, in July 2021, Nevro Corporation, a US-based medical device company, developed Senza (also known as “”””HFX””””), a high spinal cord stimulation technology for the treatment of painful diabetic neuropathy (PDN), a condition that affects up to one-third of people with diabetes (PWDs) in the United States and causes loss of sensation and pain in the lower limbs. Senza® HFX iQTM is the next generation technology that uses artificial intelligence to optimise and maintain pain alleviation based on each patient’s response. It was designed to take into consideration how different people experience pain and to help patients achieve and maintain long-term pain relief and an improved quality of life. The Senza HFX iQ system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, will be the first to use algorithms built specifically for treating chronic back and leg pain, such as severe diabetic neuropathy and non-surgical back pain.
The diabetic neuropathy market report table of contents includes:
1. Executive Summary
2. Diabetic Neuropathy Market Characteristics
3. Diabetic Neuropathy Market Trends And Strategies
4. Diabetic Neuropathy Market – Macro Economic Scenario
5. Global Diabetic Neuropathy Market Size and Growth
….
31. Global Diabetic Neuropathy Market Competitive Benchmarking
32. Global Diabetic Neuropathy Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Diabetic Neuropathy Market
34. Diabetic Neuropathy Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
